An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)

• Status: Completed
• Trial end date: 1969-12-31

Summary

To investigate the maximum tolerated dose of BIBF 1120, safety and pharmacokinetics in escalating doses administered with Vinorelbine i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).

• Phase: Phase 1

Details

• Lead Sponsor: Aktion Bronchialkarzinom e.V.
• Collaborator: Boehringer Ingelheim
• Treatments: Nintedanib; Vinblastine; Vinorelbine